Healthcare Mergers & Acquisitions and Financing Panel

 
 

“Financing Innovation and Consolidation Trends”

SAMPLE ISSUES

  • Current state of the capital markets (crossover financings, Form 10s, IPOs incl. JOBS act, follow-on offerings, royalty & structured debt financings, etc.).
  • Healthcare M&A market discussion –what is driving sector consolidation (biotech, specialty pharma, medical device, healthcare services, etc.) with specific examples and deals.
  • Insights into which deals/strategies are working well and where M&A catalyzes value creation or unique integration and other challenges.
  • Diversification strategies (R&D, licensing, acquisition of products/capabilities, geographic expansion) being pursued by major players.
  • Transformation of the payer/provider landscape including cost shifting to the consumers, geographical consolidation and technologies to track outcomes-based medicine to control costs.

Role, focus, and impact of private equity firms in healthcare dealmaking.

Jim Boylan '94
Head of Investment Banking
Leerink Swann

James (Jim) Boylan joined Leerink Swann in 2009 as a Senior Managing Director and the Head of Investment Banking. Mr. Boylan has 20+ years of experience in investment banking. Prior to joining Leerink, Jim was at Merrill Lynch & Co. for 12 years where he was a Managing Director in the healthcare group, covering pharma / biotech, healthcare services and leading the medical device franchise from 2004-2009. From 1997 to 2004, Mr. Boylan was a Managing Director in the Mergers & Acquisitions department at Merrill Lynch & Co., where he focused in healthcare and originated and led many transactions across sectors and structures. Prior to Merrill Lynch & Co., Jim was a Vice President in the healthcare group at Smith Barney. Mr. Boylan’s deal experience includes more than 100 transactions where he has helped his clients complete the full cadre of M&A and financing transactions across the pharma / biotech, medical devices, healthcare services and diagnostics & life science tools sectors. Mr. Boylan earned his MBA from Columbia University in 1994 and a B.S. from Lehigh University in 1989.

Fran Heller
Senior Vice President, Business Development
Bristol-Myers Squibb Company

Fran Heller joined Bristol-Myers Squibb in 2012 as Senior Vice President, Business Development.

In that role, Fran oversees the execution of the Company's strategy of finding external partners and innovation through licensing, collaboration and mergers and acquisitions. Prior to joining Bristol-Myers Squibb, Fran was Executive Vice President, Business Development at Exelixis.  Prior to that Fran was head of Strategic Alliances at Novartis Pharmaceuticals where she  was responsible for transactions with partners in the pharmaceutical and biotech industry as well as academic institutions worldwide. Previously she was Corporate and Intellectual Property counsel for Celera Genomics.

Fran is a Trustee at the Dana Farber Cancer Institute, teaches a business class at Stanford University on the biotech and pharmaceutical industry and has served on the board of directors of several biotech companies and universities. Fran is a member of the California State Bar, is licensed by the U.S. Patent and Trademark Office, and has a B.S. in biology from Tulane University, an M.A. in biology from American University and J.D. from Golden Gate University School of Law.

Vincent J. Lambert
Senior Managing Partner
MTS Health Partners

Mr. Lambert has been in the investment banking industry since 1993. He joined MTS as a Senior Managing Director in July, 2012. Prior to joining MTS, Mr. Lambert was a Managing Director in the Healthcare Investment Banking Group at Bank of America Merrill Lynch where he spent 13 years covering healthcare services companies.

Mr. Lambert has extensive transaction experience across a wide range of healthcare services sectors, including providers, outsourcing and distribution and managed care. Mr. Lambert has advised on over $25 billion of advisory assignments and raised over $20 billion of capital for healthcare services clients. Prior to joining Bank of America in 1999, Mr. Lambert worked in the Healthcare Investment Banking Group at CS First Boston. Mr. Lambert began his investment banking career at Dean Witter Reynolds in 1993.

Mr. Lambert graduated with a BS in Economics from The Wharton School at the University of Pennsylvania in 1993 and earned his MBA at the University of Chicago in 1998.

Matthew McAskin '04 (EMBA)
Senior Managing Director
Evercore Partners

Matthew McAskin is a Senior Managing Director of the firm's corporate advisory business. Mr. McAskin is focused on advising clients in the healthcare services sector.

Mr. McAskin was most recently a Managing Director and co-head of Healthcare Services Investment Banking at Goldman Sachs. With over 17 years of banking experience at Goldman Sachs and JPMorgan, Mr. McAskin has extensive experience advising a broad array of healthcare services companies and private equity firms, and he has advised on a number of the most recent notable transactions in the hospital, managed care, HCIT, physician services and outsourced medical services subsectors.

Mr. McAskin received his BA in Economics from the University of Michigan and received MBA degrees from Columbia Business School and London Business School.

Tim Van Biesen
Partner
Bain & Company

Tim van Biesen leads the Americas Healthcare Practice; he is based in the New York office.  Tim was previously a senior scientist in neuroscience research at Abbott Laboratories. He has 10 years of consulting experience in the healthcare industry, and more than 10 years experience as a research scientist.

Tim’s areas of expertise span the full range of healthcare sub-sectors, including manufacturers, payers, providers and services.   He has helped clients develop corporate growth strategy, R&D strategy, brand sales & marketing strategy, licensing and acquisitions, post merger integration and, manufacturing and supply chain strategy.  In addition to his work with corporate clients, Tim supports the firm’s advisory work for private equity investors in the healthcare sector.

Dr. van Biesen has published more than 30 papers in peer-reviewed journals including Nature, Proceedings of the National Academy of Science, and The Journal of Biological Chemistry, and is an inventor on two patents covering four human genes.  He is a Board member of the National Stroke Association.

He received his MBA from the Kellogg Graduate School of Management, Northwestern University and has a Ph.D. and B.Sc. in Molecular Microbiology from the University of Alberta.  Tim conducted his post-doctoral fellowship at Duke University/Howard Hughes Medical Institute in the laboratory of Dr. Robert J. Lefkowitz, the 2012 Nobel Laureate in Chemistry.